Key result
GLP-1 receptor agonists and SGLT2 inhibitors provide weight loss and cardiovascular benefits in women with obesity.
Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: In this review, the impact of obesity on cardiovascular disease in women and emerging anti-obesity pharmacologic treatments are discussed. RECENT FINDINGS: Robust evidence demonstrates the burden of obesity across the lifespan in women and links obesity to a diverse set of cardiovascular diseases. Female-specific risk factors including sex hormones and pregnancy factors intersect with obesity and cardiovascular risk. Sustained weight loss has potential for cardiovascular benefits. Recent trials demonstrate cardiovascular benefits of emerging agents with weight loss effects including GLP-1 RA and SGLT2 inhibitors in women. Treatment and prevention strategies for cardiovascular disease in obese women should include integration of weight management strategies including the targeted use of emerging pharmacologic therapies.
No takes yet. Share an insight, caveat, or question.
Behrooz et al. (2023) conducted a review in Obesity and cardiovascular diseases in women. Emerging anti-obesity pharmacologic therapies (GLP-1 RA and SGLT2 inhibitors) was evaluated on Cardiovascular benefits and weight loss. Emerging anti-obesity pharmacologic therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, demonstrate weight loss effects and cardiovascular benefits in women with obesity and CVD.
Synapse has enriched 10 related papers. Consider them for comparative context: